The Journal of Finance · 2001 · 987 citations · 2 references
Life SciencesBiotechnologyOncologyCancer PreventionChemotherapyFinancial EconomicsCancer BiotechnologyStock MarketsAttentionPublic Attention
A cancer‑curing breakthrough had been reported in *Nature* and popular media more than five months earlier. A New York Times article falsely claimed a cancer cure, causing EntreMed’s stock to jump from $12 to $85 and remain above $30 for weeks, boosting other biotech shares despite no new data.
ABSTRACT A Sunday New York Times article on a potential development of new cancer‐curing drugs caused EntreMed's stock price to rise from 12.063 at the Friday close, to open at 85 and close near 52 on Monday. It closed above 30 in the three following weeks. The enthusiasm spilled over to other biotechnology stocks. The potential breakthrough in cancer research already had been reported, however, in the journal Nature , and in various popular newspapers (including the Times ) more than five months earlier. Thus, enthusiastic public attention induced a permanent rise in share prices, even though no genuinely new information had been presented.
2
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Thomas Boehm, Judah Folkman, Timothy Browder et al. · Nature · 1997 · 1.7K citations
Medicine, Oncology, Pharmacology +16
The Evershed effect in sunspots as a siphon flow along a magnetic flux tube
B. Montesinos, John H. Thomas · Nature · 1997 · 110 citations
Natural Sciences, Astronomy, Physics +15